Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
NCT02742805 · Selina Gierer, D.O. · PHASE4 · withdrawn · last registry update 2018-05-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Selina Gierer, D.O. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGHE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-04-09Phase 3 first posted: Novartis Pharmaceuticals, Ligelizumab (NCT03907878)
- 2019-03-26Results posted on the registry: David Lang, Omalizumab + placebo (NCT00555971)
- 2019-03-19Phase 3 first posted: National Institute of Allergy and Infectious Diseases (NIAID), Omalizumab + Placebo for Omalizumab (NCT03881696)
- 2018-12-06Also stopped (withdrawn): Mayo Clinic, Omalizumab + Prednisone (NCT01893658)
- 2018-10-12Results posted on the registry: Centre Hospitalier Universitaire de Besancon, Omalizumab (NCT02262130)
- 2018-09-14Results posted on the registry: Novartis Pharmaceuticals, QGE031 + Omalizumab (NCT02477332)
- 2018-08-08Results posted on the registry: Novartis Pharmaceuticals, omalizumab + omalizumab (NCT02161562)
- 2018-07-09Phase 3 first posted: Novartis Pharmaceuticals, Ligelizumab + Omalizumab (NCT03580356)
- 2018-07-09Phase 3 first posted: Novartis Pharmaceuticals, Ligelizumab + Omalizumab (NCT03580369)
- 2018-07-09Results posted on the registry: University of Virginia, omalizumab + Rhinovirus (strain 16) (NCT02388997)
- 2018-03-27Phase 3 first posted: Hoffmann-La Roche, Omalizumab + Placebo (NCT03478930)
- 2018-03-26Results posted on the registry: Genentech, Inc., Omalizumab + Placebo (NCT02392624)
- 2018-02-19Results posted on the registry: Children's Hospital of The King's Daughters, ANTI-IGE THERAPY (XOLAIR) (NCT00283504)
- 2018-01-31Results posted on the registry: GlaxoSmithKline, Mepolizumab 100mg SC + Albuterol/salbutamol MDIs (NCT02654145)
- 2017-12-18Results posted on the registry: Kari Christine Nadeau, Omalizumab + Food Flour Buildup (NCT02626611)
- 2017-12-12Phase 3 first posted: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT03369704)
- 2017-12-11Results posted on the registry: Hoffmann-La Roche, Omalizumab (NCT01922037)
- 2017-12-11Results posted on the registry: Johns Hopkins University, Omalizumab (NCT02023151)
- 2017-11-01Phase 3 first posted: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT03328897)
- 2017-10-25Results posted on the registry: Stanford University, Xolair + Placebo (NCT02643862)
- 2017-09-26Results posted on the registry: University of North Carolina, Chapel Hill, Peanut Oral Immunotherapy + Omalizumab (NCT00932282)
- 2017-09-12Phase 3 first posted: Hoffmann-La Roche, Omalizumab + Placebo (NCT03280550)
- 2017-09-12Phase 3 first posted: Hoffmann-La Roche, Omalizumab + Placebo (NCT03280537)
- 2017-08-28Results posted on the registry: Johns Hopkins University, omalizumab (NCT00162773)
- 2017-08-28Also stopped (terminated): Johns Hopkins University, omalizumab (NCT00162773)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision